Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies
I'm PortAI, I can summarize articles.
Insilico Medicine and Qilu Pharmaceutical have signed a $120 million deal to develop cardiometabolic therapies using Insilico’s Pharma.AI platform. The agreement includes milestone payments and royalties based on net sales. Insilico will design small molecules for metabolic disorders, while Qilu will handle development and commercialization. This collaboration builds on Qilu's previous adoption of Insilico's PandaOmics in 2021. Insilico's CEO expressed optimism about the potential of AI in accelerating drug innovation for cardiometabolic diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Pharmaceutical Technology The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments